Discover Andy Brown's long and arduous journey battling a type of non-Hodgkin lymphoma and how a clinical trial altered his ...

See why investor confidence in cell and gene therapies now depends on execution and supply chain strategy—not strong science ...

Not a lot went down on the biotech deals front in August 2026, but it did see sustained collaboration in oncology and ...

The companies Moderna, Amylyx Pharmaceuticals, and Braveheart Bio bagged the biggest biotech funding rounds overall in August ...

Discover six MASH companies to keep an eye on as the race to shape the next generation of liver disease therapies heats up.

Find out what came out of the ESC Congress 2026, from phase 3 successes and failures to earlier-stage programs.

The concept of targeted therapeutics is often traced back to German Nobel laureate Paul Ehrlich’s “magic bullet” in 1907, which envisioned a single entity that could both recognize a disease target ...

Keep up with biotech layoffs in 2025! Each week, the Labiotech team tracks and analyzes layoffs across the biotech industry, offering a clear, data-driven view of trends affecting companies, ...

In recent years, biopharma has paid significantly different prices for the same underlying technology. In March 2025, AstraZeneca agreed to pay EsoBiotec, an in vivo CAR-T platform with early ...

In biotech, tension in one of a company’s most consequential relationships usually becomes visible late. A partner hesitates. The board pushes back on terms everyone assumed were settled. A financing ...

Known as the capital of peace, Geneva’s life science industry is bound to western Switzerland’s Health Valley ecosystem but is also growing in and of itself. The region suffered a blow when Merck ...